



Poliomyelitis has been largely controlled by the use of
attenuated live vaccine strains. The molecular basis of
attenuation is beginning to be understood, but the
interactions between the virus and its human host
remain mysterious.
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Although poliomyelitis is believed to be an ancient disease,
it only became a major public health concern in the early
years of the twentieth century. Improving conditions of
hygiene during the later part of the nineteenth century
resulted in exposure to the virus after the protective mater-
nal antibody had declined, leading to major epidemics in
infants [1].
Poliomyelitis is caused by poliovirus, a typical picornavirus
with a small non-lipid-containing virion approximately
27 nm in diameter. The icosahedral particle consists of
sixty copies of each of the capsid proteins VP1, VP2, VP3
and VP4, encasing a single strand of messenger sense
RNA. Polioviruses occur as serotypes 1, 2 and 3, and immu-
nity to one type is believed not to protect against the other
two. Humans are the only natural host, although primates
and old world monkeys can be infected experimentally.
Transmission is usually by the faecal-oral route, and the
virus multiplies chiefly in the small intestine and throat,
although the precise histological site has not been estab-
lished. After the initial infection, virus can be found in the
blood for a brief period, and may seed distant sites includ-
ing the central nervous system. Most infections are either
entirely asymptomatic or result in a mild illness typical of
a generalized virus infection (the minor illness); paralytic
poliomyelitis occurs in 0.1–1 % of infections.
The organisation of the poliovirus genome is shown in
Figure 1. A 5′ non-coding region of about 750 bases pre-
cedes the single large open reading frame encoding a
total protein mass of about 200 kDa. The coding region is
followed in turn by a 3′ non-coding region of 60–70 bases.
The 5′ non-coding region acts as an internal ribosome
initiation site; translation is not dependent on a free
capped 5′ terminus as for other eukaryotic messenger
RNAs [2]. The nascent viral protein is processed by
virus-encoded proteases: 2A cleaves between the struc-
tural and non-structural portions and 3C performs most
of the other cleavages. Protease 2A is also involved in an
alternative cleavage of 3CD to give 3C′ and 3D′, and in
the suppression of the normal cellular, cap-dependent,
mRNA translation in infected cells.
Live attenuated vaccines against poliomyelitis
Although the first clinically important vaccine was the for-
malin-inactivated-virus preparation developed by Salk [3],
in most parts of the world a cocktail of three live attenu-
ated strains of poliovirus, developed by Sabin [4], are used.
The three strains, one for each serotype, were selected for
the ability to grow in the gut but not in the central nervous
system. In rare instances, estimated at one per 530000
first-time vaccinees, the vaccine can itself cause
poliomyelitis; the frequency is so low as to be difficult to
measure, but is not zero. Every batch of each of the vaccine
strains produced for use is tested for neurovirulence.
Complete cDNA or free RNA copies of the genome are
infectious. It is therefore possible to generate viruses, by
rDNA techniques, that are precise recombinants between
the vaccine strains and either the precursor strain or an
isolate from a vaccine-associated case. Using this approach,
mutations that attenuated the virulent precursor strain of
the Sabin type-3 strain were found at residue 472 in the 5′
non-coding region and amino acid 91 in the capsid protein
VP3 [5]. For the type-2 strain, two mutations were associ-
ated with reversion to virulence, one at residue 481 in the
5′ non-coding region, the other at amino acid 143 in the
capsid protein VP1. The situation for the type-1 strain is
Figure 1
Organisation of the poliovirus genome
showing 5′ and 3′ non-coding regions (green),
structural proteins (red) and non-structural
proteins (blue). VPg is a small virus-encoded
protein covalently linked to the 5′ terminal
nucleotide of the genome.
more complex and as yet not completely resolved but
involves mutations in the 5′ non-coding region at residue
480, in the capsid proteins and probably elsewhere.
Molecular basis of attenuation due to mutations in the 5¢
non-coding region
The 5′ non-coding region has a complex secondary struc-
ture, as shown in Figure 2. The model is supported by a
number of lines of evidence including the general conser-
vation, between strains, of base-paired stem structures
[6,7] and the observation that three known attenuating
mutations have similar predicted effects on the stability of
Domain V. (This domain is shown in more detail for the
type-3 strain in Fig. 3.) Residue 472 is a U in the Sabin
type-3 vaccine strain giving a weak U⋅G base pair, but a C
in all other isolates examined. Similarly, in the Sabin type-
1 strain residue 480 (corresponding to 483 in Fig. 3) is a G,
giving a weak G⋅U base pair, whereas this residue is A in all
wild-type strains. In some isolates from vaccinees, the base
at position 525 (528 in Fig. 3) is mutated to a C, generating
a G⋅C from a G⋅U base pair; in others the U⋅U mismatch
found in type 1 (between residues 479 and 532 in Fig. 3) is
converted to an A⋅U pair. These observations suggest that
the structure has real in vivo physiological significance. 
The situation with the type-2 strain is not so clear, but the
base at position 481 (484 in Fig. 3) is an A, not a G as in
the wild type. This would make it possible to form an A⋅U
pair between residues 481 and 511 (514 in Fig. 3), weak-
ening the long stem in which the type-1 mutation occurs.
Reversions of the 5′ non-coding mutations are found in all
isolates from vaccine-associated cases of poliomyelitis.
Molecular basis of attenuation of the type-3 vaccine strain
due to mutation at amino acid 91 of VP3
Isolates of type-3 virus from vaccine-associated cases of
poliomyelitis rarely contain direct reversions of the phenyl-
alanine at residue 91 of VP3 to the serine found in the
virulent precursor strain. When such reversions are seen,
however, they are invariably accompanied by a mutation at
residue 54 of VP1. Other common mutations include
changes at amino acid 215 of VP2, which, again, in every
case is accompanied by a mutation at residue 54 of VP1.
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Figure 2
Proposed secondary structure of the first 620 nucleotides of the 5′
non-coding region of poliovirus. 
Figure 3
Enlarged version of domain V of Figure 2, showing the nucleotides
involved in the attenuation of the Sabin vaccine strains. Numbering and
sequence is that of the type-3 strain.
Figure 4
Pentamer of the poliovirus capsid showing VP1 (blue), VP2 (yellow),
VP3 (red) and VP4 (green). One protomer has been moved to show
the locations of the attenuating mutation at residue 91 of VP3 (pale
blue) and suppressors (white) in VP2 (residues 215 and 265) and VP3
(residues 108, 175 and 178) which lie at the interface between
adjacent protomers. 
Many of the mutations were found to be at the interface
between protomers of the virus structure, where amino
acid 91 of VP3 is also located (Fig. 4) [8,9]. It thus appeared
that the substitution of a phenylalanine for a serine at the
protomer–protomer interface weakened the structure but
that the effect could be reversed by second site mutations.
However, several lines of evidence suggest that while
some of these suppressor mutations affect promoter inter-
actions directly (Fig. 4), others do not. The mutation at
amino acid 54 is away from the interface (Fig. 5). More-
over, in one isolate the suppressor was at amino acid 18 of
VP2, which forms part of a b-pleated sheet between adja-
cent pentamers and in another there was a substitution in
residue 34 of VP1, very close to VP2 18 (Fig. 6). It is diffi-
cult to see how these substitutions could affect protomer
interactions, but they could enhance the transition from
pentamer to assembled icosahedron. Thus, a suppressor
mutation need not necessarily affect exactly the same step
as the mutation it suppresses. Substitutions at amino acid
54 of VP1 away from any interface may also affect struc-
tural transitions.
The fact that mutations seem to be second-site suppres-
sors or even multiple mutations rather than straight-
forward reversions was unexpected. However, different
vaccine-related viruses have different optimum growth
temperatures, attributable mainly to the sensitivity of
capsid assembly to temperature. The optimum for the
Sabin vaccine strain is about 35°C, whereas that for the
virulent precursor strain is about 39°C. The isolates from
vaccine-associated cases have temperature optima of
close to 37°C. The preferential occurrence of suppressor
mutations may therefore be explained by the capability of
the virus to fine tune its optimum growth temperature to
that of the human gut in which it grows.
Healthy vaccinees
Healthy vaccinees excrete virus which adapts itself to the
gut very rapidly. All the mutations observed in isolates
from vaccine-associated cases also occur in isolates from
healthy vaccinees. A summary of the changes observed and
their timing is given in Table 1 for one child studied [10].
Firstly, the mutation at residue 472 was lost within 2 days
of vaccination. Second-site suppressors of the mutation at
amino acid 91 of VP3 appeared on day 11, at which time
the virus also contained a point mutation in a known anti-
genic site of the virus. The virus also proved to be a recom-
binant between the type-3 strain, which contributed the
capsid proteins and about half of the P2 region, and the
type-2 strain, which contributed the rest. At day 42 post
vaccination, additional mutations appeared in an antigenic
site and a further recombination event occurred, in which
the extreme 3′ end of the virus was contributed by type 3
again, and the central section came from type 2. This
almost certainly arose by recombination between the type
3/type 2 recombinant and a type 2/type 3 recombinant,
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Figure 5
View of the pentamer of the poliovirus capsid from the inside of the
virion showing VP1 (blue), VP2 (yellow), VP3 (red) and VP4 (green).
The myristate linked to VP4 is shown in magenta and residue 54 of
VP1 is shown in white. One protomer has been moved to show the
internal location of VP1 54, away from the protomer interface.
Figure 6
View of the pseudo-sixfold axis of symmetry of the poliovirus capsid
from the inside of the virion showing VP1 (blue), VP2 (yellow), VP3
(red) and VP4 (green). The myristate linked to VP4 is shown in
magenta. Residue 18 of VP2 is shown in blue and residue 34 of VP1
in white. The protomer from one of the pentamers contributing to the
interactions has been moved to show the proximity of the two residues
and their location in a region of pentamer interactions. 
although type 2/3 viruses have only been found in vaccine-
associated cases [11]. This sequential appearance of differ-
ent recombinants is in our experience universal in
vaccinees excreting type-3 virus for long periods. The
recombinants are less neurovirulent than equivalent non-
recombinant viruses [12]. Despite the observed variation,
the vaccine is extremely safe and effective. The low rate of
disease associated with wild-type infection, and the rate of
selection of revertants suggest a virus well adapted to its
human host; the fact that different mutations and re-
arrangements are selected in a strikingly reproducible
sequential manner suggests that the selection pressures
exerted in the gut vary with the mutation considered. It is
likely that poliomyelitis attributed to wild-type poliovirus
will be eradicated in accordance with the goal of the World
Health Organisation before the details of the interaction
between the virus and host are fully understood.
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Table 1
Variation in Sabin type 3 related strains excreted by healthy
vaccinees.
Days post Attenuating Antigenic Recombination
vaccination mutations mutations
2 472 U→C – –
11 472 U→C VP2 167 3/2
VP218 leu–ile
42 472 U→C VP2 167 3/2/3
VP218 leu–ile
52 472 U→C VP2 167 3/2/3
VP218 leu–ile VP3 77
59 472 U→C VP2 167 3/2/3
VP218 leu–ile
73 (last isolate) 472 U→C VP2 167 3/2/3
VP218 leu–ile
